SCWD

Planning a clinical trial in sarcopenia, frailty or ageing? Bring your questions to the experts and the regulators.

At the SCWD Regulatory & Trials Update Workshop, leading researchers, EMA and FDA representatives, and industry will work through the questions that shape sarcopenia trials:
- Which endpoints are approvable?
- BIA, DEXA, CT or MRI: how should muscle mass be measured?
- SPPB, 6-minute walk, physical activity: which functional assessments matter?

Wednesday, December 9, 2026 · 13:00–15:00
Marriott Georgetown, Washington, DC, and online
Interested in joining? Contact us: society-scwd.org/contact-page/

#SCWD2026 #Sarcopenia #ClinicalTrials #RegulatoryScience #Ageing #Frailty

Incretin-based therapies are being studied across multiple organ systems, extending the clinical discussion beyond weight loss.
I’m Henning Langer, and at SCWD 2026, I’ll discuss the effects of incretin treatment, not just on the liver and heart but on the bone too.

A closer look at multi-organ effects as research continues to define the wider implications of incretin-based therapies.

10–12 December 2026 | Washington, DC
Register now: tinyurl.com/y964em5h

#SCWD2026 #SCWDConference2026 #CancerCachexiaResearch #IncretinTherapies #BoneHealth #LiverHealth #CardiovascularHealth #MuscleWasting #ClinicalManagement #PatientCare

Cachexia does not stop at the muscle, and critical illness accelerates wasting across multiple organ systems simultaneously.

Session 12 at #SCWD2026 examines cachexia across distinct critical illness contexts: chronic kidney disease, type 2 diabetes, sepsis, and liver growth and injury. Each presents a different mechanistic and clinical picture, but shared pathways in systemic wasting connect them.

Join this translational session examining how disease-specific drivers of cachexia converge, and what that means for understanding and intervening in muscle loss in critically ill patients.
Join us in Washington, DC, 10–12 December 2026.
Register early: tinyurl.com/y964em5h

#SCWD2026 #SCWDConference2026 #Cachexia #CancerCachexiaResearch #MuscleWasting #CriticalIllness #Sepsis #KidneyDisease #TranslationalResearch

Incretin-based therapies are changing how we approach weight management, but their effects extend beyond changes in body weight.

At SCWD 2026, we’ll discuss multi-organ wasting during incretin treatment, with a focus on muscle health and the broader effects of these therapies across skeletal muscle and other organs. A clinically focused discussion at the intersection of sarcopenia, adiposity and cardiometabolic disease, and what these considerations mean for patient care.

10–12 December 2026 | Washington, DC
Register now: tinyurl.com/y964em5h

#SCWD2026 #SCWDConference2026 #CancerCachexiaResarch #Sarcopenia #IncretinTherapies #MuscleWasting #MuscleHealth #Adiposity #CardiometabolicHealth #ClinicalManagement

Cancer cachexia remains an important clinical consideration in oncology, affecting up to 80% of advanced cancer patients.

I’m Jeffrey Crawford, and at SCWD 2026, I’ll deliver the “Hippocrates” Clinical Science Keynote Lecture, sharing an oncologist’s perspective on cancer and cachexia and the importance of recognising its clinical impact.

I look forward to discussing how greater understanding of cachexia can support clinical management and better patient outcomes.

10–12 December 2026 | Washington, DC
Register now: tinyurl.com/y964em5h

#SCWD2026 #SCWDConference2026 #CancerCachexiaResarch #CancerCachexia #Cachexia #Oncology #ClinicalScience #ClinicalManagement #PatientOutcomes